Efficacy and Safety of Belumosudil in Subjects With Diffuse Cutaneous Systemic Sclerosis
Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
This is a phase 2, open-label, single-cohort, multicenter trial of belumosudil in subjects
with Diffuse Cutaneous Systemic Sclerosis (dcSSc). An estimated total of 12 to 15 subjects
will receive belumosudil 200 mg administered orally (PO) twice daily (BID) for 52 weeks. The
primary analysis will be at 24 weeks.